Background: Few small studies have described hospital-acquired infections (HAIs) occurring in patients with COVID-19. Research Question: What characteristics in critically ill patients with COVID-19 are associated with HAIs and how are HAIs associated with outcomes in these patients? Study Design and Methods: Multicenter retrospective analysis of prospectively collected data including adult patients with severe COVID-19 admitted to eight Italian hub hospitals from February 20, 2020, through May 20, 2020. Descriptive statistics and univariate and multivariate Weibull regression models were used to assess incidence, microbial cause, resistance patterns, risk factors (ie, demographics, comorbidities, exposure to medication), and impact on outcomes (ie, ICU discharge, length of ICU and hospital stays, and duration of mechanical ventilation) of microbiologically confirmed HAIs. Results: Of the 774 included patients, 359 patients (46%) demonstrated 759 HAIs (44.7 infections/1,000 ICU patient-days; 35% multidrug-resistant [MDR] bacteria). Ventilator-associated pneumonia (VAP; n = 389 [50%]), bloodstream infections (BSIs; n = 183 [34%]), and catheter-related BSIs (n = 74 [10%]) were the most frequent HAIs, with 26.0 (95% CI, 23.6-28.8) VAPs per 1,000 intubation-days, 11.7 (95% CI, 10.1-13.5) BSIs per 1,000 ICU patient-days, and 4.7 (95% CI, 3.8-5.9) catheter-related BSIs per 1,000 ICU patient-days. Gram-negative bacteria (especially Enterobacterales) and Staphylococcus aureus caused 64% and 28% of cases of VAP, respectively. Variables independently associated with infection were age, positive end expiratory pressure, and treatment with broad-spectrum antibiotics at admission. Two hundred thirty-four patients (30%) died in the ICU (15.3 deaths/1,000 ICU patient-days). Patients with HAIs complicated by septic shock showed an almost doubled mortality rate (52% vs 29%), whereas noncomplicated infections did not affect mortality. HAIs prolonged mechanical ventilation (median, 24 days [interquartile range (IQR), 14-39 days] vs 9 days [IQR, 5-13 days]; P < .001), ICU stay (24 days [IQR, 16-41 days] vs 9 days [IQR, 6-14 days]; P = .003), and hospital stay (42 days [IQR, 25-59 days] vs 23 days [IQR, 13-34 days]; P < .001). Interpretation: Critically ill patients with COVID-19 are at high risk for HAIs, especially VAPs and BSIs resulting from MDR organisms. HAIs prolong mechanical ventilation and hospitalization, and HAIs complicated by septic shock almost double mortality. Trial Registry: ClinicalTrials.gov; No.: NCT04388670; URL: www.clinicaltrials.gov

Hospital-Acquired Infections in Critically Ill Patients With COVID-19 / Grasselli, G.; Scaravilli, V.; Mangioni, D.; Scudeller, L.; Alagna, L.; Bartoletti, M.; Bellani, G.; Biagioni, E.; Bonfanti, P.; Bottino, N.; Coloretti, I.; Cutuli, S. L.; De Pascale, G.; Ferlicca, D.; Fior, G.; Forastieri, A.; Franzetti, M.; Greco, M.; Guzzardella, A.; Linguadoca, S.; Meschiari, M.; Messina, A.; Monti, G.; Morelli, P.; Muscatello, A.; Redaelli, S.; Stefanini, F.; Tonetti, T.; Antonelli, M.; Cecconi, M.; Foti, G.; Fumagalli, R.; Girardis, M.; Ranieri, M.; Viale, P.; Raviglione, M.; Pesenti, A.; Gori, A.; Bandera, A.. - In: CHEST. - ISSN 0012-3692. - 160:2(2021), pp. 454-465. [10.1016/j.chest.2021.04.002]

Hospital-Acquired Infections in Critically Ill Patients With COVID-19

Biagioni E.;Coloretti I.;Meschiari M.;Girardis M.;Raviglione M.;Bandera A.
2021

Abstract

Background: Few small studies have described hospital-acquired infections (HAIs) occurring in patients with COVID-19. Research Question: What characteristics in critically ill patients with COVID-19 are associated with HAIs and how are HAIs associated with outcomes in these patients? Study Design and Methods: Multicenter retrospective analysis of prospectively collected data including adult patients with severe COVID-19 admitted to eight Italian hub hospitals from February 20, 2020, through May 20, 2020. Descriptive statistics and univariate and multivariate Weibull regression models were used to assess incidence, microbial cause, resistance patterns, risk factors (ie, demographics, comorbidities, exposure to medication), and impact on outcomes (ie, ICU discharge, length of ICU and hospital stays, and duration of mechanical ventilation) of microbiologically confirmed HAIs. Results: Of the 774 included patients, 359 patients (46%) demonstrated 759 HAIs (44.7 infections/1,000 ICU patient-days; 35% multidrug-resistant [MDR] bacteria). Ventilator-associated pneumonia (VAP; n = 389 [50%]), bloodstream infections (BSIs; n = 183 [34%]), and catheter-related BSIs (n = 74 [10%]) were the most frequent HAIs, with 26.0 (95% CI, 23.6-28.8) VAPs per 1,000 intubation-days, 11.7 (95% CI, 10.1-13.5) BSIs per 1,000 ICU patient-days, and 4.7 (95% CI, 3.8-5.9) catheter-related BSIs per 1,000 ICU patient-days. Gram-negative bacteria (especially Enterobacterales) and Staphylococcus aureus caused 64% and 28% of cases of VAP, respectively. Variables independently associated with infection were age, positive end expiratory pressure, and treatment with broad-spectrum antibiotics at admission. Two hundred thirty-four patients (30%) died in the ICU (15.3 deaths/1,000 ICU patient-days). Patients with HAIs complicated by septic shock showed an almost doubled mortality rate (52% vs 29%), whereas noncomplicated infections did not affect mortality. HAIs prolonged mechanical ventilation (median, 24 days [interquartile range (IQR), 14-39 days] vs 9 days [IQR, 5-13 days]; P < .001), ICU stay (24 days [IQR, 16-41 days] vs 9 days [IQR, 6-14 days]; P = .003), and hospital stay (42 days [IQR, 25-59 days] vs 23 days [IQR, 13-34 days]; P < .001). Interpretation: Critically ill patients with COVID-19 are at high risk for HAIs, especially VAPs and BSIs resulting from MDR organisms. HAIs prolong mechanical ventilation and hospitalization, and HAIs complicated by septic shock almost double mortality. Trial Registry: ClinicalTrials.gov; No.: NCT04388670; URL: www.clinicaltrials.gov
160
2
454
465
Hospital-Acquired Infections in Critically Ill Patients With COVID-19 / Grasselli, G.; Scaravilli, V.; Mangioni, D.; Scudeller, L.; Alagna, L.; Bartoletti, M.; Bellani, G.; Biagioni, E.; Bonfanti, P.; Bottino, N.; Coloretti, I.; Cutuli, S. L.; De Pascale, G.; Ferlicca, D.; Fior, G.; Forastieri, A.; Franzetti, M.; Greco, M.; Guzzardella, A.; Linguadoca, S.; Meschiari, M.; Messina, A.; Monti, G.; Morelli, P.; Muscatello, A.; Redaelli, S.; Stefanini, F.; Tonetti, T.; Antonelli, M.; Cecconi, M.; Foti, G.; Fumagalli, R.; Girardis, M.; Ranieri, M.; Viale, P.; Raviglione, M.; Pesenti, A.; Gori, A.; Bandera, A.. - In: CHEST. - ISSN 0012-3692. - 160:2(2021), pp. 454-465. [10.1016/j.chest.2021.04.002]
Grasselli, G.; Scaravilli, V.; Mangioni, D.; Scudeller, L.; Alagna, L.; Bartoletti, M.; Bellani, G.; Biagioni, E.; Bonfanti, P.; Bottino, N.; Coloretti, I.; Cutuli, S. L.; De Pascale, G.; Ferlicca, D.; Fior, G.; Forastieri, A.; Franzetti, M.; Greco, M.; Guzzardella, A.; Linguadoca, S.; Meschiari, M.; Messina, A.; Monti, G.; Morelli, P.; Muscatello, A.; Redaelli, S.; Stefanini, F.; Tonetti, T.; Antonelli, M.; Cecconi, M.; Foti, G.; Fumagalli, R.; Girardis, M.; Ranieri, M.; Viale, P.; Raviglione, M.; Pesenti, A.; Gori, A.; Bandera, A.
File in questo prodotto:
File Dimensione Formato  
8_main.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 470.71 kB
Formato Adobe PDF
470.71 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1258710
Citazioni
  • ???jsp.display-item.citation.pmc??? 93
  • Scopus 92
  • ???jsp.display-item.citation.isi??? 95
social impact